XFOREST Therapeutics

xFOREST Therapeutics is a biotech company focused on RNA-targeted small-molecule drug discovery using RNA-library-based HTS.

Operating in health & longevity based in Kyoto, Japan, XFOREST Therapeutics operates.

Profile

Company Overview – xFOREST Therapeutics xFOREST Therapeutics is a Kyoto University iPS cell institute spin-out founded in 2020, dedicated to overcoming “undruggable” diseases through RNA-targeted small molecule therapeutics. By unlocking the therapeutic potential of RNA structures, we aim to deliver novel treatment options for patients with few existing therapies. Our proprietary FOREST platform enables high-throughput, structure-based discovery of RNA-binding small molecules, a previously inaccessible domain for small molecule drugs The platform’s core engine, MatrixFOREST, biochemically profiles binding interactions across thousands of RNA structural motifs and tens of thousands of compounds. This "library × library" approach generates single-nucleotide resolution binding profiles, enabling efficient discovery of high-affinity binders (KD < 100 nM) and guiding SAR-based lead optimization. SpliceVerse, our complementary platform, screens splicing modulators and their mechanisms of action (MoA) through multiplexed assays. It supports high-throughput selectivity evaluation and provides detailed mechanistic insights at the nucleotide level resolution. xFOREST’s approach solves key li

As a business in health & longevity, XFOREST Therapeutics is listed here with the public details available about it.

The company is recorded as being based in Kyoto, Japan.

Its current recorded stage is Plug and Play portfolio startup.

Website: www.xforestx.com